StockData
VolitionRx Ltd logo

VolitionRx Ltd (VNRX) stock

VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.19−0.01 (-5.56%)

Close on Nov 17, 2026Market cap $2.58MP/E –Yield –

VolitionRx price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

VolitionRx's price to sales ratio was 1.0× on Nov 11, 2026, against 24.0× a year earlier. Over the last 4 years it ranged from 1.0× to 496.0×, with a median of 58.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×−18.0
2025Dec 31, 202519.0×−24.1
2024Dec 31, 202443.1×−43.5
2023Dec 29, 202386.6×−291.5
2022Sep 30, 2022378.1×−113.2
2013Apr 30, 2013491.3×−4.7
2012Dec 31, 2012496.0×–

More VolitionRx figures

See a number that looks wrong?